Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for diseases involving angiogenesis

A technology of angiogenesis and disease, applied in the field of disease composition, can solve the problems of not being completely effective, toxic to patients, etc.

Inactive Publication Date: 2009-05-20
BAUSCH & LOMB INC
View PDF27 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Such large doses can be toxic to patients
Furthermore, targeting only a single event in the VEGF-induced angiogenic cascade may not disrupt the cascade completely and thus the therapy may not be fully effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for diseases involving angiogenesis
  • Combination therapy for diseases involving angiogenesis
  • Combination therapy for diseases involving angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] In general, the present invention provides compositions and methods for preventing, treating or ameliorating disorders involving angiogenesis.

[0021] In one aspect, the invention provides such compositions and methods for targeting two or more sources of VEGF activity in such diseases, resulting in at least reduced availability of active VEGF.

[0022] In another aspect, the invention provides such compositions and methods that target two or more sources of VEGF activity in such diseases. In one embodiment, such compositions or methods substantially eliminate, reduce or inhibit the production or availability of active VEGF.

[0023] In yet another aspect, the present invention provides such compositions and methods for targeting two or more sources of VEGF activity in disorders that support tumor growth, such as those exhibiting rapidly and extensively expanding abnormal angiogenesis.

[0024] Accumulating evidence has established that overactivity of VEGF plays an i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compounds that interact with and inhibit a downstream activity of extracellular VEGF, compounds that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compounds that reduce a level of expression of VEGF. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition.

Description

Background of the invention [0001] The present invention relates to compositions and methods for preventing, treating or ameliorating disorders involving angiogenesis. In particular, the present invention relates to such compositions and methods that target two or more modes of action of vascular endothelial growth factor ("VEGF") in such diseases. More specifically, the invention relates to such compositions and methods that target two or more modes of action of VEGF in eye diseases involving angiogenesis. [0002] Each year, more than six million patients are newly diagnosed with serious eye diseases. Intraocular neovascularization is associated with a variety of eye diseases, often resulting in severe loss of vision and eventual blindness. Among these diseases, diabetic retinopathy ("DR") and age-related macular degeneration ("AMD") are the most prevalent. DR affects 16 million Americans with diabetes, one-third of whom remain undiagnosed and untreated. AMD is the leadi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P43/00A61K45/06
CPCA61K45/06A61P43/00
Inventor K·W·沃德P·蒂尔
Owner BAUSCH & LOMB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com